Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart… (NCT07326631) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure
120 participantsStarted 2026-01-01
Plain-language summary
To assess the effect of Finerinone on slowing renal function decline and improving cardiovascular outcomes, particularly heart failure risk, in patients with diabetic CKD.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged ≥18 years.
* Diagnosed cases of type 2 diabetes mellitus.
* Chronic kidney disease with eGFR 25-90 mL/min/1.73m² and/or UACR ≥30 mg/g.
* On stable ACE inhibitor or ARB therapy for at least 4 weeks.
* Serum potassium ≤4.8 mmol/L.
* Provided written informed consent.
Exclusion Criteria:
* Symptomatic heart failure (NYHA class II-IV).
* eGFR \<25 mL/min/1.73m² or on maintenance dialysis.
* Known non-diabetic kidney disease.
* Recent major cardiovascular event (within 30 days).
* Serum potassium \>4.8 mmol/L or history of severe hyperkalaemia.
* Contraindication or hypersensitivity to finerenone.
* Pregnancy or lactation.
* Any condition limiting compliance or follow-up.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Number of Participants with Renal Function Decline post finerinone therapy
Timeframe: From enrollment to the end of treatment at 06 months
2
Number of Participants with Heart Failure (HF) Event post finerinone therapy
Timeframe: 6 month
3
eGFR Measurement
Timeframe: 06 months
4
Number of Participants with Albuminuria
Timeframe: 06 months
5
Number of Participants with Hyperkalaemia post treatment
Timeframe: 06 months
6
Number of Participants with Cardiovascular (CV) Event post treatment with finerinone therapy
Timeframe: 06 months
Trial details
NCT IDNCT07326631
SponsorCollege of Physicians and Surgeons Pakistan